Alcon's core business remains fundamentally sound, with revenue growth of 8.7% in 2026Q2 and gross margins expanding to 59.3%, the highest in the series. However, the deliberate escalation in R&D spending to $663M in 2026Q2, up from a ~$240M quarterly average,...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth remained stable at 8.7% in 2026Q2 with gross margin expanding to 59.3%, but operating margin collapsed to 0.4% from 15.5% in the prior quarter due to a surge in R&D spending to $663M.
Alcon's mission focuses on providing cutting-edge vision products that improve quality of life, from cataract solutions to dry eye relief.
The company maintains a strong position in surgical and vision care, supported by a robust innovation pipeline and exposure to long-term growth in ophthalmology.
Alcon's intraocular lenses offer advanced solutions for cataract patients, enabling a full range of vision post-surgery.
Trailing total returns as of 10/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | $0.84+9.1% vs $0.77 | $2.8B+2.5% vs $2.7B |
Q2 2026 May 5, 2026 | $0.85+6.3% vs $0.80 | $2.7B+0.4% vs $2.6B |
Q1 2026 Feb 24, 2026 | $0.78-1.3% vs $0.79 | $2.6B-1.9% vs $2.7B |
Q4 2025 Nov 11, 2025 | $0.79+2.6% vs $0.77 | $2.6B-3.6% vs $2.7B |
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
CRDO expands its AI connectivity portfolio with the 1.6T ZeroFlap Active Light Cable, offering lower power consumption, enhanced reliability and extended reach.
[url="]Credo Technology Group Holding Ltd[/url] (Credo) (NASDAQ: CRDO), an innovator in providing connectivity at scale through fast, reliable, and energy-effic
Algoma Central Co. (TSE: ALC - Get Free Report) passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of C$23.31 and traded as high as C$23.99. Algoma Central shares last traded at C$23.90, with a volume of 4,445 shares trading hands. Algoma Central Price Performance The
Benchmark ALC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alcon Inc. (ALC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $70.63 | $34.45B | 35.67 | 4.94% | 9.42% | 4.5% | 0.47% | |
| $25.65 | $13.25B | -14.66 | 5.72% | -9.27% | -16.67% | — | |
| $86.00 | $9.8B | 26.30 | 4.03% | 2.96% | 8.38% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $566.76 | $44.71B | 43.33 | 10.42% | 25.03% | 71.96% | — | |
| $90.09 | $51.87B | 49.23 | 11.55% | 15.43% | 9.66% | — |
Alcon Inc. (ALC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ALC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alcon Inc. (ALC) stock FAQ — growth, dividends, profitability & financials explained
Alcon Inc. (ALC) reported $10.81B in revenue for fiscal year 2025. This represents a 66% increase from $6.52B in 2015.
Alcon Inc. (ALC) grew revenue by 4.9% over the past year. Growth has been modest.
Yes, Alcon Inc. (ALC) is profitable, generating $639.3M in net income for fiscal year 2025 (9.4% net margin).
Yes, Alcon Inc. (ALC) pays a dividend with a yield of 0.47%. This makes it attractive for income-focused investors.
Alcon Inc. (ALC) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
Alcon Inc. (ALC) generated $1.68B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
